Guided Therapeutics (GTHP) Stock Price, News & Analysis

Company Overview

Guided Therapeutics, Inc. is a medical device company focused on the development and commercialization of non‐invasive optical diagnostic platforms for women’s health. Its flagship product, the LuViva® Advanced Cervical Scan, combines hyperspectral and reflectance imaging to support the early detection of cervical epithelial abnormalities. By capturing tissue fluorescence and reflectance signatures in real time, LuViva is designed to augment traditional visual inspection methods and assist clinicians during colposcopic evaluations.

The company secured 510(k) clearance from the U.S. Food and Drug Administration in 2013 and obtained CE marking for distribution within the European Union, enabling it to market its technology across multiple regions. Guided Therapeutics collaborates with academic and research institutions—including the National Cancer Institute—to validate its imaging algorithms through clinical studies conducted in both the United States and Europe. These partnerships have informed ongoing refinements to the LuViva platform and supported expansion of its distribution channels via direct sales and strategic alliances.

Founded in 1993 and headquartered in Melbourne, Florida, Guided Therapeutics leverages a multidisciplinary management team with expertise in biomedical engineering, oncology, and regulatory affairs. Building on the core technology behind LuViva, the company is exploring additional applications in gynecologic and dermatologic diagnostics. Its long-term strategy aims to extend its non‐invasive optical imaging capabilities to address a broader range of clinical needs in early disease detection.

Key Stats

• Today's Range: $0.23 to $0.23
• 50-Day Range: $0.18 to $0.25
• 52-Week Range: $0.12 to $0.54
• Volume: 1,485 shs
• Average Volume: 11,610 shs
• Market Capitalization: $22.01 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Guided Therapeutics Stock Analysis - MarketRank™

Guided Therapeutics scored higher than 2% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Guided Therapeutics.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Guided Therapeutics is -5.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Guided Therapeutics is -5.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.13% of the float of Guided Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Guided Therapeutics has a short interest ratio ("days to cover") of 0.92, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Guided Therapeutics has recently increased by 14.57%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Guided Therapeutics does not currently pay a dividend.

Dividend Growth

Guided Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Guided Therapeutics this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Guided Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

66.83% of the stock of Guided Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

9.69% of the stock of Guided Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 5/15/2026
• Today: 6/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Medical Equipment
• Current Symbol: OTCMKTS:GTHP
• CIK: 924515
• Web: www.guidedinc.com
• Phone: (770) 242-8723
• Fax: 770-242-8639
• Employees: 5
• Year Founded: 1992

Profitability

• EPS (Trailing Twelve Months): ($0.04)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$3.20 million
• Net Margins: N/A
• Pretax Margin: -426.21%
• Return on Equity: N/A
• Return on Assets: -274.24%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.15
• Quick Ratio: 0.07

Sales & Book Value

• Annual Sales: $770 thousand
• Price / Sales: 28.59
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.09) per share
• Price / Book: -2.53

Miscellaneous

• Outstanding Shares: 96,540,000
• Free Float: 32,021,000
• Market Cap: $22.01 million
• Optionable: Not Optionable
• Beta: 0.74